Over the last 15 years, colistin has been used for the treatment of VAP caused by resistant A. baumannii. The clinical cure rate of VAP patients receiving colistin alone or combined with other antibiotics has been reported to be highly variable, between 15% and 85.7% [17-22]. In our study, the rate was found to be 64.2%.